In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Pfizer's upcoming earnings report, and what the Big Pharma has in store for 2013.
Foolish Preview: Pfizer Earnings
What to expect from the big pharma's fourth quarter.
By Dave Williamson – Jan 28, 2013 at 8:09PM EST
Read Next
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Stocks Mentioned
Pfizer
NYSE: PFE
$26.66
(+0.19%)+$0.05
Bristol Myers Squibb
NYSE: BMY
$60.05
(-1.14%)-$0.69
Incyte
NASDAQ: INCY
$95.54
(-1.84%)-$1.79
AbbVie
NYSE: ABBV
$229.04
(-1.43%)-$3.31
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.